AVEO Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- AVEO Pharmaceuticals's estimated annual revenue is currently $44.2M per year.
- AVEO Pharmaceuticals's estimated revenue per employee is $193,750
- AVEO Pharmaceuticals's total funding is $553.6M.
Employee Data
- AVEO Pharmaceuticals has 228 Employees.
- AVEO Pharmaceuticals grew their employee count by 5% last year.
AVEO Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | VP Clinical Operations | Reveal Email/Phone |
6 | VP Program Management | Reveal Email/Phone |
7 | SVP Marketing | Reveal Email/Phone |
8 | VP Technical Operations | Reveal Email/Phone |
9 | VP, Compliance & Regulatory Counsel | Reveal Email/Phone |
10 | Controller | Reveal Email/Phone |
AVEO Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is AVEO Pharmaceuticals?
AVEO Oncology is founded on a unique drug discovery and development approach called the Human Response Platform™. With it, we aim to translate cancer biology insights into next generation therapeutics targeted to specific patients living with cancer who will benefit most.
keywords:N/A
$553.6M
Total Funding
228
Number of Employees
$44.2M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AVEO Pharmaceuticals News
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its...
... President and Chief Executive Officer of AVEO Oncology, ... and Senior Vice President of Business Development at Synta Pharmaceuticals.
AVEO Pharmaceuticals, Inc. (AVEO) stock has fallen -12.84% over the last 12 months, and the average rating from Wall Street analysts is a...
→ Aveo Oncology was hit with a fresh setback on Thursday. Its 2013-rejected tivozanib is still not ready for a new marketing application, the company said, citing FDA feedback. The agency recommended that the drug developer not submit the application as preliminary o ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $34.3M | 228 | 2% | $23.6M |
#2 | $7.5M | 229 | -5% | N/A |
#3 | $51.1M | 230 | -5% | N/A |
#4 | $34.6M | 230 | 6% | $71.5M |
#5 | $36M | 231 | 2% | $114.5M |